Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002475 · ClinicalTrials.gov registry record · Phase 2
Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
A Phase 2 study of Breast Cancer and Lung Cancer, sponsored by St. Vincent Medical Center - Los Angeles.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT00002475 is a Phase 2 study of Breast Cancer and Lung Cancer that has completed, run by St. Vincent Medical Center - Los Angeles. The registered enrollment target is 40 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00002475, a Phase 2 study of Breast Cancer and Lung Cancer, has completed, sponsored by St. Vincent Medical Center - Los Angeles.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Vaccines made from a patient's tumor tissue may make the body build an immune response to kill tumor cells. Chemotherapy combined with vaccine therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining cyclophosphamide with tumor cell vaccine in treating patients who have metastatic cancer or cancer at high risk of recurrence.
Conditions Studied
Interventions
- BIOLOGICAL recombinant interferon alfa
- BIOLOGICAL sargramostim
- BIOLOGICAL allogeneic tumor cell vaccine
- BIOLOGICAL autologous tumor cell vaccine
- BIOLOGICAL recombinant interferon gamma
Study Locations (1)
California
- St. Vincent Medical Center - Los Angeles - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 1991-04 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002475
The ClinicalTrials.gov registry entry for NCT00002475 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is St. Vincent Medical Center - Los Angeles, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which recombinant interferon alfa is the first listed.
NCT00002475 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00002475 about?
NCT00002475 is a clinical study titled "Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer". RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Vaccines made from a patient's tumor tissue may make the body build an immune response to kill tumor cells. Chemotherapy combined with vaccine therapy may kill more tumor cells...
What is the current status of trial NCT00002475?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 1991-04. Estimated completion is 2009-06.
What conditions does trial NCT00002475 study?
This clinical trial studies the following conditions: Breast Cancer, Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Kidney Cancer.
What interventions are being tested in trial NCT00002475?
The interventions under investigation include: recombinant interferon alfa (BIOLOGICAL), sargramostim (BIOLOGICAL), allogeneic tumor cell vaccine (BIOLOGICAL), autologous tumor cell vaccine (BIOLOGICAL), recombinant interferon gamma (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002475?
This trial is sponsored by St. Vincent Medical Center - Los Angeles, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002475 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.